Background: Dietary l-leucine or its metabolite 𝛽-hydroxy-𝛽-methylbutyrate (HMB) has a crucial role in the muscle protein metabolism of broilers during the first few-week growing period. The present study aimed to evaluate the effects of l-leucine (LLPD) or HMB (HLPD) supplementation in a low-protein diet (20%, LPD) until 21 days old on performance, carcass weight, muscle yield and meat quality, as well as intestinal morphometry, in broiler chickens.
Results: From days 1-42, LPD decreased body weight gain and feed intake (FI) and increased feed conversion ratio compared to a standard protein diet (22%, SPD). The LLPD and HLPD did not affect FI, but the LLPD decreased the body weight gain and increased the feed conversion ratio compared to the SPD. The LPD group had lower body and muscle weights than other groups. Compared to LPD, HLPD increased dressing percentage. The LPD decreased the serum insulin-like growth factor-1 content compared to the SPD and LLPD. The duodenal villus height of the LPD and LLPD broilers was smaller than those of the SPD and HLPD birds. The HLPD broilers had lower duodenal villus width than the SPD birds. The duodenal crypt depth and ileal mucosal thickness were higher in the HLPD group than in other groups. The HLPD and LLPD enhanced the ileal villus height compared to the SPD. The LLPD and HLPD treatments did not affect meat quality traits compared to the SPD treatment.
Conclusion: Dietary HMB could be a conducive approach to reducing dietary protein for broilers until 21 days old. © 2023 The Authors. Journal of The Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jsfa.13023 | DOI Listing |
Heliyon
November 2024
Trakya University School of Medicine, Department of Medical Biochemistry, Edirne, Turkey.
Arthritis Res Ther
December 2024
Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Daigaku-Machi 2-7, Takatsuki, Osaka, 569-8686, Japan.
Background: This study investigated poor prognostic factors for the relapse of interstitial lung disease (ILD) in patients with microscopic polyangiitis (MPA) after remission induction therapy.
Methods: We enrolled patients diagnosed with MPA complicated by ILD according to the Chapel Hill Consensus definition from 2001 to 2023 in multiple institutions in the REVEAL cohort. All patients who were treated with immunosuppressive therapy were followed up, and those who relapsed with ILD were extracted in this study.
Immunol Res
December 2024
Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Natural killer (NK) cells are a cytotoxic subset of innate lymphoid cells and have key roles in antitumoral immunity. This study evaluates the roles of immune checkpoint receptors on NK cell phenotype and functions both before and after circulation through tumor tissue. Twenty non-small cell lung cancer patients undergoing surgery and 21 healthy controls were included.
View Article and Find Full Text PDFPaediatr Drugs
December 2024
PEDeus Ltd, Zurich, Switzerland.
Background: Drug dosing recommendations in paediatrics are mainly based on the age and bodyweight of the child. Because of the limited amount of label information, several paediatric drug formularies have been developed. This study compares anti-infective drug dosing recommendations across three European formularies.
View Article and Find Full Text PDFClin Cancer Res
December 2024
University of Parma, Parma, Italy.
Purpose: To uncover the underpinnings of acquired resistance (AR) to immunotherapy (IO), we determined whether distinctive clinico-pathological, radiomic and peripheral blood (PB) immune-inflammatory features reflect oligo- and systemic (sys)-AR in advanced NSCLC patients undergoing immune checkpoints inhibitors.
Experimental Design: On 105 consecutive IO-treated advanced NSCLC, PB immunophenotypes, cytokines and CT-derived radiomic features (RFs), extracted from primary and merged metastatic lesions, were prospectively collected at baseline (T0) and first disease assessment (T1, 9-12 weeks), and their delta (Δ) variation [(T1-T0)/T0] computed. AR, defined as progression after initial response (complete/partial) or stable disease ≥ 6 months, was subdivided according to the number of new and/or progressive lesions in oligoAR (≤3) and sysAR (>3).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!